ROCKVILLE, Md., Aug. 24 Stem cell companyNeuralstem, Inc. (OTC Bulletin Board: NRLS) today announced that its shareshave been accepted for listing on the American Stock Exchange(R) (Amex(R))under the symbol CUR. Neuralstem shares are expected to begin trading on Amexon August 27, 2007.
"Moving to the Amex is the next logical step for Neuralstem. It is aresult of the continuous and significant progress the company has made in eachand every phase of its activity, and of an increasing awareness of the companyand its prospects on the part of the financial community," said Richard Garr,Neuralstem President and Chief Executive Officer.
The approval is contingent upon the company being in compliance with allapplicable listing standards on the date its stock begins trading on theAmex(R) and may be rescinded if the company is not in compliance with suchstandards.
Neuralstem's patent-protected technology enables, for the first time, theability to produce neural stem cells of the human brain and spinal cord incommercial quantities, and the ability to control the differentiation of thesecells into mature, physiologically relevant human neurons and glia. TheCompany expects that its first Investigational New Drug (IND) application willbe for the treatment of Ischemic Paraplegia, a form of paraplegia thatsometimes results from the surgery to repair aortic aneurysms and for whichthere is no effective treatment The Company hopes to submit its initial INDapplication to the FDA and begin its first human trial during calendar year2007.
Major Central Nervous System diseases targeted by the Company withresearch programs currently underway include: Ischemic Paraplegia, TraumaticSpinal Cord Injury, ALS, and Parkinson's disease. The company's cells recentlyextended the life of rats with ALS (Lou Gehrig's disease) in a paper publishedin the journal TRANSPLANTATION, and were deemed viable for continued work inneurodegenerative spinal conditions. Neuralstem cells also recently reversedparalysis in rats with Ischemic Spastic Paraplegia, a form of paralysis thatcan result from the surgery to repair aortic aneurysms, as reported inNEUROSCIENCE (http://www.neuroscience-ibro.com/). The company has alsodeveloped immortalized human neural stem cells for in-vitro use in drugdevelopment for the academic and pharmaceutical markets. For furtherinformation, please visit http://www.neuralstem.com.
Cautionary Statement Regarding Forward Looking Information
This presentation may contain forward-looking information aboutNeuralstem, Inc. which are intended to be covered by the safe harbor forforward-looking statements provided by the Private Securities LitigationReform Act of 1995. Forward- looking statements are statements that are nothistorical facts. These statements can be identified by the use offorward-looking terminology such as "believe," "expect," "may," "will,""should," "project," "plan," "seek," "intend," or "anticipate" or the negativethereof or comparable terminology, and include discussions of strategy, andstatements about industry trends and Neuralstem's future performance,operations and products. This and other "Risk Factors" contained inNeuralstem's public filings with the SEC should be read in connection withthis release. For further information on Neuralstem, please review thecompany's filings with the SEC including its Annual Report filed on Form10-KSB for the period ended December 31, 2006, as well as the company'ssubsequent filings.
SOURCE Neuralstem, Inc.